Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

BTX

Brooklyn ImmunoTherapeut... (BTX)

Brooklyn ImmunoTherapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BTX
FechaHoraFuenteTítuloSímboloCompañía
11/05/202315:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
10/05/202305:02Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202306:02Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202306:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
05/05/202305:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
25/04/202308:02Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/04/202315:31Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
04/04/202316:15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
04/04/202316:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/12/202215:31Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
16/12/202216:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
14/12/202215:31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
06/12/202217:52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
02/12/202216:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
11/10/202207:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate UpdatesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
26/07/202206:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck CancerNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
17/06/202216:00GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/06/202206:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Board ChangesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
31/05/202206:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual MeetingNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
27/05/202215:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-QNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
19/05/202207:23GlobeNewswire Inc.Amarin Announces Appointment of New Directors and Board Leadership ChangesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
29/04/202215:35Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
21/04/202206:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular MedicinesNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
15/04/202216:10Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
15/04/202215:15GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial ResultsNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
01/04/202205:31Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
09/03/202215:15GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private PlacementNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
07/03/202207:00GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Announces $12 Million Private PlacementNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
20/01/202206:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of DirectorsNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
13/01/202207:30GlobeNewswire Inc.Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property PortfolioNASDAQ:BTXBrooklyn ImmunoTherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BTX

Su Consulta Reciente

Delayed Upgrade Clock